Patent Portfolio Overview
ImmunoBrain Checkpoint is developing a pipeline of novel immune therapies to treat neurodegeneration and other forms of brain disorders by harnessing peripheral immunity.
The ImmunoBrain team and Prof. Schwartz group at the Weizmann Institute of Science, were the first to demonstrate that targeting specific immune checkpoint pathways can be utilized as a therapeutic approach for neurodegenerative disease. Based on these findings, ImmunoBrain has been developing several patent families.
First is our platform IP, a portfolio of use/method patents covering a wide range of immune checkpoint inhibitors for the treatment of neurodegenerative disorders. Additional patent families cover a proprietary fully human anti-PD-L1 antibody, IBC-Ab002. This antibody was designed with specific modifications based on its intended mechanism of action, and tailored for treatment of neurodegenerative diseases.
